PPT-Dolutegravir + 2 NRTIs versus Darunavir + RTV + 2 NRTIs

FLAMINGO Dolutegravir 2 NRTIs versus Darunavir RTV 2 NRTIs FLAMINGO Study Design Source Clotet B et al Lancet 2014383222231 Dolutegravir TDFFTC or ABC3TC n 242 Darunavir Ritonavir . New pricing agreement will speed up access to generic, dolutegravir (DTG)-based fixed dose combinations (FDCs) . HIV positive people in low- and middle-income countries including South Africa can be treated for around R900 (US $75 a year) . By. Bani Tamraz, . Pharm.D. ., Ph.D.. Associate Clinical Professor. School of Pharmacy. Research Interests. Identification of . genetic . determinants of drug response. Translate to new diagnostics and treatment strategies . Sam Lam, . PharmD. Annie Vong, . PharmD. 2/3/2017. Available HCV treatment DAAs. Epclusa. (. sofosbuvir. / . velpatasvir. ). Harvoni. (. sofosbuvir. / . ledipasvir. ). Zepatier. (. grazoprevir. / . GS-US-216-0114. . Gallant JE. JID 2013;208:32-9. GS-US-216-0114. Design. Objective. Non inferiority of COBI compared with RTV at W48: % HIV RNA < 50 c/mL . by intention to treat, snapshot analysis (lower limit for the 95% CI for the difference = -12%, 95% power). Joseph J. Eron, Jr, MD. Professor of Medicine. University of North Carolina. Chapel Hill, North Carolina. Panelists. Constance Benson. Hyman Scott. Annie . Luetkemeyer. Robert . Schooley. Financial Relationships With Commercial Entities. PROTEA Trial. Darunavir/r . M. onotherapy. versus Triple Therapy . PROTEA. : Study Design. Source: . Antinori. A, et al. . J Int AIDS Soc. 2014;17:19525.. Darunavir 800 mg QD. + Ritonavir 100 mg . QD. DUAL-GESIDA. Dual Maintenance ART with RTV-Boosted Darunavir + . Lamivudine. DUAL . GESIDA: . Study Design. Source: . Pulido. . F, . et al. . Clin Infect . Dis..  . 2017;65:2112-8.. DRV + RTV + 3TC. Dovato. ). Last Updated: November 28, 2022. Prepared by:. Brian R. Wood, MD. David H. Spach, MD. Dolutegravir-Lamivudine. Photograph courtesy of . ViiV. INSTI. NRTI. 50 mg. 300 mg. Dolutegravir-Lamivudine. Virologically. Suppressed. OLE Trial. LPV-RTV + . 3TC vs. LPV. -RTV + 2 NRTIs. in . Virologically. Suppressed. OLE: . Study Design. Source: . Arribas. JR, et al. . Lancet Infect Dis. . 2015;15:. 785-92.. SPRING-2 Study. Dolutegravir. versus Raltegravir. SPRING-2: Design. Source: . Raffi. F, et al. Lancet. 2013;381:735-43.. Dolutegravir. : 50 mg QD. Fixed-dose NRTI backbone*. (n = 411). Raltegravir. Prepared by:. Brian R. Wood, MD. David H. Spach, MD. Last Updated: January 28, 2021. Dolutegravir (. Tivicay. ) . INSTI. Tivicay. . [TIV-eh-kay]. Dolutegravir. Treatment Naïve. : 50 mg once daily with or without food. POWER 1 and 2. Darunavir. /. r versus other PIs in Treatment-Experienced . POWER 1 and 2. : Study Design. Source: . Clotet. B, et al. . Lancet. . 2007;369:. 1169-78.. Darunavir BID + RTV BID + OBR . RADAR Trial. Raltegravir. + Darunavir/r versus TDF-FTC + Darunavir/r. RADAR: Study Design. Source: . Bedimo. RJ, et al. . PLoS. One. 2014;9:e106221.. Darunavir QD + Ritonavir QD + Raltegravir BID . HIV-NAT . 017. SQV and . LPV-RTV . in Treatment-Experienced Children . HIV-NAT . 017: . Study . Design. Source: . Kosalaraksa. P, et al. . Pediatr. Infect Dis J. . 2008;27:. 623-8. . SQV + LPV-RTV +/- 3TC.